In a nutshell This study investigated how people with myeloma responded to vaccines against COVID-19. It found that roughly half of the patients with multiple myeloma (MM) and most patients with other types of myeloma had protection against serious illness after the vaccine. The response to the vaccine was weaker for patients using certain treatments,...
Read More
In a nutshell This study described the real-world effectiveness and safety of arsenic trioxide (ATO; Trisenox) combined with all-trans retinoic acid (ATRA; Vesanoid), without chemotherapy, in patients with newly diagnosed acute promyelocytic leukemia (APL). The authors concluded that a combination of ATO and ATRA showed good results for the...
Read More
In a nutshell This study investigated the relationships among depression and anxiety, diet, and disease activity or physical function in patients with rheumatoid arthritis (RA). The data showed that there was a relationship between depression and lower fish intake frequency in these patients. Some background RA is a chronic inflammatory...
Read More
In a nutshell This study reviewed the current minimally invasive surgical (MIS) approaches for the treatment of patients with rectal cancer (RC). Some background Rectal cancer (RC) is one of the most common types of cancer worldwide. RC involves the final part of the large intestine or rectum. RC can be treated by surgical removal of the tumor. Some...
Read More
In a nutshell This study looked at the use of two types of stem cell transplant (SCT) in the treatment of T-cell lymphoma. It found that both haploidentical and umbilical cord blood SCT were good options for these patients. Some background T-cell lymphoma is a cancer affecting a certain type of blood cell called T-cells. T-cells are...
Read More
In a nutshell This study assessed whether robot-assisted radical prostatectomy (RARP) improves lower urinary tract symptoms (LUTS) and quality of life (QoL) in patients with prostate cancer (PCa). The data showed an improvement in LUTS and QoL in patients with previously moderate or severe LUTS, 12 months after RARP. Some background PCa...
Read More
In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...
Read More
In a nutshell The study aimed to investigate whether reduced-intensity conditioning (RIC) hemopoietic stem cell transplantation (HSCT) improves the outcomes of patients with chronic lymphocytic leukemia (CLL) with and without Richter's transformation (RT). This study concluded that this treatment may be suitable in early...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of venetoclax (Venclexta) combined with intensive chemotherapy in patients aged 65 or younger with acute myeloid leukemia (AML). This study concluded that venetoclax added to intensive chemotherapy was safe and effective in these...
Read More
In a nutshell This study looked at long-term treatment with ticagrelor (Brilique) after percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD). It found that compared to patients treated with placebo, those treated with ticagrelor were less likely to have a major cardiovascular event (MACE). Some...
Read More
In a nutshell This study looked at the effects of long-term physiotherapy (6 months or more) on patients with Parkinson's disease. It found that patients doing long-term physiotherapy had fewer symptoms during the "off" medication phase, and needed lower doses of levodopa (Sinemet) to manage their symptoms compared to patients not...
Read More
In a nutshell This study compared two treatment regimes for HER2 positive breast cancer; pyrotinib (Irene) plus vinorelbine (Navelbine), or lapatinib (Tykerb) plus capecitabine (Xeloda). It found that pyrotinib plus vinorelbine (PV) improved survival without cancer progressing compared to lapatinib plus capecitabine (LC). Some background...
Read More
